A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Two Companies Colloborate on a New Combined Solution to More Efficiently & Effectively Diagnose & Treat AFib & POAF

In An Effort to Improve Patient Outcomes

Peerbridge Health and Native Cardio Inc. recognize the postoperative challenges the 500,000+ cardiac surgery patients in the US face each year, with more than 20% developing postoperative atrial fibrillation (POAF). As a result, these companies are collaborating on a new combined solution to more efficiently and effectively diagnose and treat atrial fibrillation (AFib) and POAF, improving patient outcomes.

Without a way to predict which patients will develop POAF, every cardiac surgery patient is potentially at risk. In addition, there is no current standard of care for monitoring these patients after discharge for development of chronic AFib. Negative outcomes related to POAF include increased risk of stroke and death, extended length of stay in the hospital, hospital readmission following discharge, and risk of developing chronic atrial fibrillation. This results in billions of dollars wasted each year on poor health outcomes.

“POAF is the most frequent complication after cardiac surgery, and the incidence rate is on the rise,” said Dr. Joseph Pergolizzi, Founder and President of NativeCardio, Inc. “We’re happy to partner with Peerbridge to ensure cardiac patients have access to improved monitoring solutions that better address this serious health concern and restore their quality of life.”

Peerbridge Health and Native Cardio’s collaboration will elevate the importance of proactively monitoring and treating for POAF after a patient is discharged from the hospital following surgery. Physicians will be able to prescribe one unified solution to monitor patient progress and quickly treat POAF if complications occur. The powerful combination of the Peerbridge Cor™, a best-in-class wireless electrocardiogram (ECG) patch, and Native Cardio’s Rhythm MakerTM, a device that addresses POAF immediately by delivering an ultra-low shock to the patient’s heart, have the potential to negate poor patient outcomes, prevent hospital readmission, and better manage post-surgical patients.

“Currently, there is a lack of focus and coordination around the detection and treatment of POAF,” said Adrian Gilmore, CEO at Peerbridge Health. “Our collaboration with Native Cardio will ensure there is an integrated solution to address this challenge, while also improving patient outcomes and reducing costs for providers and payors.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy